Grants for Public housing authorities - Federal

This funding opportunity supports researchers in developing and validating assays to discover new chemical compounds that could lead to treatments for mental health disorders.

This grant provides funding for researchers to evaluate and develop effective strategies to prevent driving under the influence of multiple substances, particularly focusing on high-risk populations.

This funding opportunity provides financial support to organizations working with Eswatini's Ministry of Health to strengthen its capacity in managing and responding to HIV, TB, and related public health challenges.

This funding opportunity provides financial support for developing short courses that equip nurse scientists and researchers with the skills needed to advance firearm injury prevention research, focusing on health equity and innovative methodologies.

This funding opportunity provides financial support for researchers to analyze existing health datasets related to heart, lung, and blood diseases, as well as sleep disorders, in order to address important scientific questions and improve health outcomes.

This funding opportunity provides up to $500,000 for researchers to conduct innovative studies that inform tobacco product regulation and public health, with a focus on understanding tobacco use, its health effects, and addiction.

Reissue of RFA-NS-18-020: Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.

This funding opportunity supports collaborative research projects led by independent investigators to advance the understanding and treatment of infectious and immune-mediated diseases.

Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

This funding opportunity supports researchers in conducting observational studies or validating biomarkers related to dental, oral, and craniofacial diseases, aiming to improve prevention, diagnosis, and treatment through prospective data collection and analysis.

This funding opportunity provides financial support for research consortia focused on improving the diagnosis and treatment of rare diseases through collaborative, patient-centered clinical studies involving multiple institutions and patient advocacy groups.

The "Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences" grant aims to fund educational activities that inspire individuals from diverse and underrepresented backgrounds to pursue careers or further studies in biomedical and behavioral sciences research.

This funding opportunity supports innovative research projects that aim to improve health outcomes and promote health equity in the U.S. by addressing social determinants of health and enhancing healthcare delivery systems.

This funding opportunity supports researchers in analyzing existing data from a major study on adolescent brain development and health to uncover new insights and address health disparities among youth.

This funding opportunity supports the development of innovative tools and methodologies to study the human virome, inviting a diverse range of organizations to enhance our understanding of how viruses impact human health and disease.

The "Neuropathological Interactions Between COVID-19 and ADRD" grant aims to fund research that investigates how COVID-19 affects the brain and cognitive outcomes in models with Alzheimer's Disease and related dementias (AD/ADRD), how it accelerates these conditions in early stages, and how it potentially increases the risk for future AD/ADRD.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

This grant provides funding for researchers and institutions to develop innovative technologies that can record and modulate neural activity, with a focus on advancing neuroscience through proof-of-concept projects.

The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

This funding opportunity supports research institutions and organizations in developing innovative technologies to study how neural cell groups in rodents respond to addictive substances, aiming to deepen our understanding of addiction-related behaviors.